




The relative strengths and weaknesses of Zevra Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zevra Therapeutics INC compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 3.5% points. The greatest weakness of Zevra Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is 57%, being 192% points below the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	23,721
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,004
Liabilities, Non-Current	689
Other Assets	1,272
Other Compr. Net Income	0
Other Expenses	1,510
Other Liabilities	80,619
Other Net Income	-689
Other Revenues	0
Property and Equipment	1,753
Research and Development	41,759
Selling, General and Administrative Expense	12,508

Output Variable	Value in 1000 USD
Assets	26,746
Liabilities	93,312
Expenses	55,777
Revenues	0
Stockholders Equity	-66,566
Net Income	-56,466
Comprehensive Net Income	-56,466
BaseVar	88,262
ECR before LimitedLiability	-336%
Economic Capital Ratio	57%